Edition:
India

Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

179.94USD
23 May 2018
Change (% chg)

$1.58 (+0.89%)
Prev Close
$178.36
Open
$177.12
Day's High
$179.99
Day's Low
$176.66
Volume
2,183,661
Avg. Vol
4,704,123
52-wk High
$201.23
52-wk Low
$152.16

Chart for

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN... (more)

Overall

Beta: 1.40
Market Cap(Mil.): $135,588.20
Shares Outstanding(Mil.): 729.67
Dividend: 1.15
Yield (%): 2.48

Financials

  AMGN.O Industry Sector
P/E (TTM): 16.90 30.95 32.75
EPS (TTM): 11.00 -- --
ROI: 11.98 14.84 14.38
ROE: 26.43 16.34 16.07

U.S. FDA approves Amgen drug for prevention of migraines

Amgen Inc won U.S. Food and Drug Administration approval on Thursday for the first drug in a new class designed to prevent migraine headaches in adults.

18 May 2018

UPDATE 4-U.S. FDA approves Amgen drug for prevention of migraines

May 17 Amgen Inc won U.S. Food and Drug Administration approval on Thursday for the first drug in a new class designed to prevent migraine headaches in adults.

18 May 2018

CORRECTED-UPDATE 3-U.S. FDA approves Amgen drug for prevention of migraines

May 17 Amgen Inc won U.S. Food and Drug Administration approval on Thursday for the first drug in a new class designed to prevent migraine headaches in adults.

18 May 2018

BRIEF-Novartis, Amgen Announce FDA Approval Of Aimovig Treatment For Migraine Prevention

* NOVARTIS AND AMGEN ANNOUNCE FDA APPROVAL OF AIMOVIG™ (ERENUMAB-AOOE), A NOVEL TREATMENT DEVELOPED SPECIFICALLY FOR MIGRAINE PREVENTION

18 May 2018

Pfizer's biosimilar of Amgen, J&J's anemia treatments gets FDA nod

Pfizer Inc's Retacrit was approved by U.S. health regulators as a biosimilar to current anemia treatments from Amgen Inc and Johnson & Johnson on Tuesday, setting it up to compete against more established brands.

15 May 2018

UPDATE 2-Pfizer's biosimilar of Amgen, J&J's anemia treatments gets FDA nod

* Shares of Amgen, JNJ fall in afternoon trading (Adds analyst comments, updates shares)

15 May 2018

FDA approves Pfizer's biosimilar of Amgen's Epogen

May 15 The U.S. Food and Drug Administration on Tuesday approved Pfizer Inc's biosimilar of Amgen Inc's anemia treatment Epogen.

15 May 2018

Regeneron/Sanofi to cut price of heart drug in Express Scripts deal

May 1 Regeneron Pharmaceuticals and Sanofi will cut the net price of their expensive cholesterol drug for Express Scripts customers in exchange for greater patient access, with some savings to be shared with consumers, the companies said on Tuesday.

01 May 2018

BRIEF-Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 Aspire Study To Kyprolis Label

* AMGEN RECEIVES POSITIVE CHMP OPINION TO ADD OVERALL SURVIVAL RESULTS FROM THE PHASE 3 ASPIRE STUDY TO KYPROLIS® (CARFILZOMIB) LABEL Source text for Eikon: Further company coverage:

30 Apr 2018

BRIEF-Amgen Says In April, Co's Board Increased The Amount Authorized Under Co's Stock Repurchase Program By An Additional $5 Bln - SEC Filing

* AMGEN INC SAYS IN APRIL, CO'S BOARD INCREASED THE AMOUNT AUTHORIZED UNDER CO'S STOCK REPURCHASE PROGRAM BY AN ADDITIONAL $5.0 BILLION - SEC FILING Source text: (https://bit.ly/2FftYIV) Further company coverage:

25 Apr 2018

Earnings vs. Estimates